Merck Mounts $3 Billion Revamp as Keytruda Price Pressure Looms
Merck & Co. is slashing $3 billion from its annual spending as it braces for off-brand competition to its cancer drug Keytruda, the best-selling...
Dow, S&P 500, Nasdaq Set to Open Up; Fed Rate Meeting; Trump, China Trade Talks; UnitedHealth, Tesla, Sarepta, More Movers
Stocks looked set to open in the green on Tuesday as the tariff relief rally kept rolling on, and investors braced for a Federal...
Dow, S&P 500, Nasdaq Set to Open Up; Fed Rate Meeting; Trump, China Trade Talks; UnitedHealth, Tesla, Sarepta, More Movers
Stocks looked set to open in the green on Tuesday as the tariff relief rally kept rolling on, and investors braced for a Federal...
Moody’s Stock: Upside Still Attractive Over The Next 2 Years (NYSE:MCO)
Moody's remains a strong Buy with resilient earnings, pricing power, and growth in private credit & GenAI, offering a clear path to 16% upside....
Moody’s Stock: Upside Still Attractive Over The Next 2 Years (NYSE:MCO)
Moody's remains a strong Buy with resilient earnings, pricing power, and growth in private credit & GenAI, offering a clear path to 16% upside....
